Brexafemme, New Treatment For Vaginal Yeast Infection, Faces Considerable Pricing And Reimbursement Challenges Brexafemme is a recently approved drug for vaginal yeast infection; the first non-azole treatment. The drug’s sponsor, Scynexis, has made progress in the commercial market, facilitating access. But payer pricing and reimbursement challenges remain.